ES2423493T3 - Antagonistas de los GABA-esteroides y su uso para el tratamiento de trastornos del SNC - Google Patents

Antagonistas de los GABA-esteroides y su uso para el tratamiento de trastornos del SNC Download PDF

Info

Publication number
ES2423493T3
ES2423493T3 ES05801885T ES05801885T ES2423493T3 ES 2423493 T3 ES2423493 T3 ES 2423493T3 ES 05801885 T ES05801885 T ES 05801885T ES 05801885 T ES05801885 T ES 05801885T ES 2423493 T3 ES2423493 T3 ES 2423493T3
Authority
ES
Spain
Prior art keywords
gaba
pregnan
3beta
steroids
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05801885T
Other languages
English (en)
Spanish (es)
Inventor
Torbjörn BÄCKSTRÖM
Per Lundgren
Ming-De Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Umecrine AB
Original Assignee
Umecrine AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine AB filed Critical Umecrine AB
Application granted granted Critical
Publication of ES2423493T3 publication Critical patent/ES2423493T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES05801885T 2004-11-18 2005-11-07 Antagonistas de los GABA-esteroides y su uso para el tratamiento de trastornos del SNC Expired - Lifetime ES2423493T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62951104P 2004-11-18 2004-11-18
US629511P 2004-11-18
PCT/SE2005/001671 WO2006054938A1 (en) 2004-11-18 2005-11-07 Gaba-steroid antagonists and their use for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
ES2423493T3 true ES2423493T3 (es) 2013-09-20

Family

ID=36407411

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05801885T Expired - Lifetime ES2423493T3 (es) 2004-11-18 2005-11-07 Antagonistas de los GABA-esteroides y su uso para el tratamiento de trastornos del SNC

Country Status (11)

Country Link
US (2) US8114860B2 (OSRAM)
EP (1) EP1812009B1 (OSRAM)
JP (1) JP4914368B2 (OSRAM)
CN (1) CN101076340B (OSRAM)
AU (1) AU2005307151B2 (OSRAM)
BR (1) BRPI0518359A2 (OSRAM)
CA (1) CA2585359C (OSRAM)
DK (1) DK1812009T3 (OSRAM)
ES (1) ES2423493T3 (OSRAM)
MX (1) MX2007006032A (OSRAM)
WO (1) WO2006054938A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054938A1 (en) 2004-11-18 2006-05-26 Umecrine Ab Gaba-steroid antagonists and their use for the treatment of cns disorders
HUE036410T2 (hu) * 2006-11-21 2018-07-30 Asarina Pharma Ab Pregnán és androsztán szteroidok alkalmazása CNS rendellenességek kezelésére szolgáló gyógyszerkészítmény elõállítására
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
US20110086828A1 (en) * 2009-10-07 2011-04-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of alcohol abuse and alcoholism using modulators of neurosteroid binding sites on gabaa receptors
MX2012008257A (es) 2010-01-14 2012-11-21 Umecrine Mood Ab Una composicion farmaceutica que comprende 3-beta-hidroxi-5-alfa-p regnan-20-ona con propiedades mejoradas de almacenamiento y solubilidad.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4614499A (en) * 1985-04-29 1986-09-30 Universite Laval Simulator for use as a neurosurgical aid in determining potential paths for the implantation of probes through the human body
WO1999045931A1 (en) * 1998-03-11 1999-09-16 Baeckstroem Torbjoern Epiallopregnanolone in the treatment of cns disorders
FR2806303B1 (fr) * 2000-03-17 2002-09-27 Inst Nat Sante Rech Med Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments
US20030125311A1 (en) * 2000-03-17 2003-07-03 Etienne-Emile Baulieu Compounds capable of binding with the cytoskeleton
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
WO2006054938A1 (en) 2004-11-18 2006-05-26 Umecrine Ab Gaba-steroid antagonists and their use for the treatment of cns disorders

Also Published As

Publication number Publication date
WO2006054938A1 (en) 2006-05-26
JP4914368B2 (ja) 2012-04-11
CN101076340B (zh) 2011-01-12
US8114860B2 (en) 2012-02-14
DK1812009T3 (da) 2013-08-05
CN101076340A (zh) 2007-11-21
EP1812009B1 (en) 2013-05-15
EP1812009A1 (en) 2007-08-01
US8372824B2 (en) 2013-02-12
AU2005307151B2 (en) 2011-10-20
EP1812009A4 (en) 2010-08-11
US20120142657A1 (en) 2012-06-07
BRPI0518359A2 (pt) 2008-11-18
JP2008525317A (ja) 2008-07-17
CA2585359C (en) 2013-01-08
AU2005307151A1 (en) 2006-05-26
MX2007006032A (es) 2007-10-17
US20080070876A1 (en) 2008-03-20
CA2585359A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
ES2394639T3 (es) Esteroides de pregnano para utilización en el tratamiento de trastornos del CNS
Qiu et al. Neuroprotection provided by dietary restriction in rats is further enhanced by reducing glucocortocoids
PT1322336E (pt) Método de aumentar as concentrações de testosterona e esteróides relacionados em mulheres
JP2006515890A (ja) 末梢血管疾患の症状のための方法及びキット
Nisbett et al. Sex and hormonal status influence the anxiolytic-like effect of oxytocin in mice
US8372824B2 (en) GABA-steroid antagonists and their use for the treatment of CNS disorders
ES2287252T5 (es) Uso de derivados de 2-alfa-ciano-4-alfa, 5-alfa-epoxiandrostan-17-beta-ol-3-ona para disminuir los niveles de cortisol sérico y para el tratamiento de afecciones clínicas asociadas a los mismos
RU2413516C2 (ru) Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
BR112020019538A2 (pt) Antagonistas gaba-a para tratar transtornos por abstinência de substância
RU2355406C2 (ru) Средство для стимуляции роста мотонейронов спинного мозга растущего организма млекопитающих и способ его применения
JP7179739B2 (ja) 医学的治療における使用のための３－β－ヒドロキシ－５－α－プレグナン－２０－オン
Hysek et al. P. 1. c. 009 Role of the norepinephrine uptake transporter in the mechanism of action of MDMA (Ecstasy)